1
|
Lebrun F, Violle N, Letourneur A, Muller C, Fischer N, Levilly A, Orset C, Sors A, Vivien D. Post-acute delivery of α5-GABAA antagonist, S 44819, improves functional recovery in juvenile rats following stroke. Exp Neurol 2021; 347:113881. [PMID: 34597681 DOI: 10.1016/j.expneurol.2021.113881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 09/21/2021] [Accepted: 09/24/2021] [Indexed: 11/04/2022]
Abstract
Hypo-excitability was reported in the peri-infarct tissue following stroke, an effect counteracted by a blockage of α5-GABAA receptors in adult rodents. Our present study aims to evaluate the effect of a selective α5-GABAA receptor antagonist, S 44819, in stroke in juvenile animals. We have set up and characterized an original model of transient ischemic stroke in 28 day-old Sprague-Dawley rats (45-min occlusion of the middle cerebral artery by intraluminal suture). In this model, S 44819 (1, 3 and 10 mg/kg, b.i.d) was orally administered from day 3 to day 16 after stroke onset. Sensorimotor recovery was assessed on day 1, day 9 and day 16 after stroke onset. Results show that rats treated with S 44819 at the doses of 3 and 10 mg/kg displayed a significant improvement of the neurological deficits (neuroscore) on day 9 and day 16, when compared with animals treated with vehicle. Grip-test data analysis reveals that rats treated with S 44819 at the dose of 3 mg/kg displayed a better recovery on day 9 and day 16. These results are in agreement with those previously observed in adult rats, demonstrating that targeting α5-GABAA receptors improves neurological recovery after stroke in juvenile rats.
Collapse
Affiliation(s)
- Florent Lebrun
- ETAP-Lab, STROK@LLIANCE, 13 Rue du Bois de la Champelle, 54500 Vandoeuvre-les-Nancy, France; Normandie Univ, UNICAEN, INSERM, GIP Cyceron, Institut Blood and Brain @Caen-Normandie (BB@C), UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), Caen, France
| | - Nicolas Violle
- ETAP-Lab, STROK@LLIANCE, 13 Rue du Bois de la Champelle, 54500 Vandoeuvre-les-Nancy, France
| | - Annelise Letourneur
- ETAP-Lab, STROK@LLIANCE, 13 Rue du Bois de la Champelle, 54500 Vandoeuvre-les-Nancy, France
| | - Christophe Muller
- ETAP-Lab, STROK@LLIANCE, 13 Rue du Bois de la Champelle, 54500 Vandoeuvre-les-Nancy, France
| | - Nicolas Fischer
- ETAP-Lab, STROK@LLIANCE, 13 Rue du Bois de la Champelle, 54500 Vandoeuvre-les-Nancy, France
| | - Anthony Levilly
- ESRP (European Stroke Research Platform), Centre Universitaire de Ressources Biologiques (CURB), Université Caen Basse Normandie, Caen, France
| | - Cyrille Orset
- Normandie Univ, UNICAEN, INSERM, GIP Cyceron, Institut Blood and Brain @Caen-Normandie (BB@C), UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), Caen, France; ESRP (European Stroke Research Platform), Centre Universitaire de Ressources Biologiques (CURB), Université Caen Basse Normandie, Caen, France
| | - Aurore Sors
- Institut de Recherches Internationales Servier, Suresnes, France
| | - Denis Vivien
- Normandie Univ, UNICAEN, INSERM, GIP Cyceron, Institut Blood and Brain @Caen-Normandie (BB@C), UMR-S U1237, Physiopathology and Imaging of Neurological Disorders (PhIND), Caen, France; Department of Clinical Research, CHU Caen-Normandie, Caen, France.
| |
Collapse
|
2
|
Chabriat H, Bassetti CL, Marx U, Audoli-Inthavong ML, Sors A, Lambert E, Wattez M, Hermann DM, ALTHAUS K, AMARO S, BAE HJ, BAK Z, BARBARINI L, BASSI P, BAZAN R, BERECZKI D, BERKOWICZ T, BERROUSCHOT J, BLACQUIERE D, BROLA W, BUTCHER K, CARDONA P, CHA JK, CLOUD G, COHEN D, CORDONNIER C, CSANYI A, CZLONKOWSKA A, DAVIS S, DAWSON J, DE KLIPPEL N, DENIER C, DESFONTAINES P, DIENER HC, DIOSZEGHY P, DIPPEL DW, DORADO L, FOLYOVICH A, FREITAS GR, FRIEDRICH MA, FRYZE W, GAGLIARDI RJ, GOTTSCHAL M, GRIMLEY R, GROND M, GRÖSCHEL K, HOSSEINI H, HWANG Y, KALLMUENZER B, KHAN U, KIM JS, KLEINIG T, KOVES A, LAGO MARTIN A, LASEK-BAL A, LEMBO G, LEMMENS R, LINDERT R, PORCELLO MARRONE LC, MARTINEZ ZABALETA M, MAS JL, MASJUAN VALLEJO J, MAZIGHI M, MINELLI C, MISTRI A, MOLINA C, MONICHE ALVAREZ F, CABRAL MORO CH, MULLENERS W, NABAVI D, NEAU JP, O'BRIEN B, OVARY C, PANCZEL G, PARK MS, PHAN T, RAGAB S, REJDAK K, RODRIGUEZ DE FREITAS G, ROFFE C, ROQUER GONZALEZ J, ROVER L, SAMPAIO SILVA G, SCHELLINGER P, SEGURA MARTIN T, SHAW L, SIBON I, SKODA O, SMADJA D, SOBOLEWSKI P, SODA H, SPRIGG N, SWIAT M, SZAPARY L, SZEGEDI N, TONI D, VALIKOVICS A, VANHOOREN G, VECSEI L, WEIN T, WONG A, XIMENEZ CARRILLO A. Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2020; 19:226-233. [DOI: 10.1016/s1474-4422(20)30004-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Revised: 12/16/2019] [Accepted: 01/08/2020] [Indexed: 10/25/2022]
|
3
|
Chabriat H, Bassetti CL, Marx U, Picarel-Blanchot F, Sors A, Gruget C, Saba B, Wattez M, Audoli ML, Hermann DM. Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study. Trials 2020; 21:136. [PMID: 32014032 PMCID: PMC6998064 DOI: 10.1186/s13063-020-4072-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Accepted: 01/13/2020] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND The GABAA-α5 receptor antagonist S44819 is a promising candidate to enhance functional recovery after acute ischemic stroke (IS). S44819 is currently evaluated in this indication; RESTORE brain study started in Dec 2016 and was completed in March 2019. METHODS/DESIGN The study is a 3-month international, randomized, double-blind, parallel group, placebo-controlled phase II multicentre study. Patients in 14 countries who suffered an IS leading to a moderate or severe deficit defined by NIHSS score ranging from 7 to 20 and are aged between 18 to 85 years are included between 3 and 8 days after the stroke onset. Approximately 580 patients are to be included. The primary objective of the study is to demonstrate the superiority of at least one of the two doses of S44819 (150 or 300 mg bid) compared to placebo on top of usual care on functional recovery measured with the modified Rankin scale at 3 months. Comparisons between two doses of S44819 and placebo are assessed with ordinal logistic regression evaluating the odds of shifting from one category to the next in the direction of a better outcome at day 90. Secondary objectives include the evaluation of S44819 effects on neurological examination using the National Institute of Health Stroke Scale total score, activities of daily living using the Barthel Index total score, and cognitive performance using the Montreal Cognitive Assessment scale total score and Trail Making Test times. Safety and tolerability of the two doses of S44819 will also be analyzed. DISCUSSION The RESTORE BRAIN study might represent the first proof of concept study of an innovative therapeutic approach that is primarily based on enhancing functional recovery after IS. TRIAL REGISTRATION Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event, an international, multi-centre, randomized, double-blind placebo-controlled phase II study. ClinicalTrials.gov, NCT02877615; Eudract 2016-001005-16. Registered 24 August 2016.
Collapse
Affiliation(s)
- Hugues Chabriat
- Department Neurology, Lariboisière Hospital, APHP and University Denis Didierot, Paris 7, Paris, France.,FHU Neuro Vasc, Paris, France.,INSERM U1141, Paris, France
| | | | - Ute Marx
- Institut de Recherches Internationales Servier (IRIS), 50 rue Carnot, 92284, Suresnes Cedex, France
| | | | - Aurore Sors
- Institut de Recherches Internationales Servier (IRIS), 50 rue Carnot, 92284, Suresnes Cedex, France
| | - Celine Gruget
- Institut de Recherches Internationales Servier (IRIS), 50 rue Carnot, 92284, Suresnes Cedex, France.
| | - Barbara Saba
- Institut de Recherches Internationales Servier (IRIS), 50 rue Carnot, 92284, Suresnes Cedex, France
| | - Marine Wattez
- Institut de Recherches Internationales Servier (IRIS), 50 rue Carnot, 92284, Suresnes Cedex, France
| | - Marie-Laure Audoli
- Institut de Recherches Internationales Servier (IRIS), 50 rue Carnot, 92284, Suresnes Cedex, France
| | - Dirk M Hermann
- Chair of Vascular Neurology, Dementia and Ageing Research, Department of Neurology, University Hospital Essen, Hufelandstraße 55, 45122, Essen, Germany
| |
Collapse
|
4
|
Hermann DM, Saba B, Sors A, Bassetti CL. Preclinical concepts and results with the GABA A antagonist S44819 in a mouse model of middle cerebral artery occlusion. Neural Regen Res 2019; 14:1517-1518. [PMID: 31089046 PMCID: PMC6557109 DOI: 10.4103/1673-5374.255963] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- Dirk M Hermann
- Departments of Neurology, University Hospital Essen, Essen, Germany
| | - Barbara Saba
- Institut de Recherches Internationales Servier, Suresnes, France
| | - Aurore Sors
- Institut de Recherches Internationales Servier, Suresnes, France
| | | |
Collapse
|
5
|
Riddy DM, Cook AE, Shackleford DM, Pierce TL, Mocaer E, Mannoury la Cour C, Sors A, Charman WN, Summers RJ, Sexton PM, Christopoulos A, Langmead CJ. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H 3 receptor antagonists. Neuropharmacology 2019; 144:244-255. [PMID: 30359639 DOI: 10.1016/j.neuropharm.2018.10.028] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 09/18/2018] [Accepted: 10/19/2018] [Indexed: 02/09/2023]
Abstract
The histamine H3 receptor is a G protein-coupled receptor (GPCR) drug target that is highly expressed in the CNS, where it acts as both an auto- and hetero-receptor to regulate neurotransmission. As such, it has been considered as a relevant target in disorders as varied as Alzheimer's disease, schizophrenia, neuropathic pain and attention deficit hyperactivity disorder. A range of competitive antagonists/inverse agonists have progressed into clinical development, with pitolisant approved for the treatment of narcolepsy. Given the breadth of compounds developed and potential therapeutic indications, we assessed the comparative pharmacology of six investigational histamine H3 agents, including pitolisant, using native tissue and recombinant cells. Whilst all of the compounds tested displayed robust histamine H3 receptor inverse agonism and did not differentiate between the main H3 receptor splice variants, they displayed a wide range of affinities and kinetic properties, and included rapidly dissociating (pitolisant, S 38093-2, ABT-239) and slowly dissociating (GSK189254, JNJ-5207852, PF-3654746) agents. S 38093-2 had the lowest histamine H3 receptor affinity (pKB values 5.7-6.2), seemingly at odds with previously reported, potent in vivo activity in models of cognition. We show here that at pro-cognitive and anti-hyperalgesic/anti-allodynic doses, S 38093-2 preferentially occupies the mouse sigma-1 receptor in vivo, only engaging the histamine H3 receptor at doses associated with wakefulness promotion and neurotransmitter (histamine, ACh) release. Furthermore, pitolisant, ABT-239 and PF-3654746 also displayed appreciable sigma-1 receptor affinity, suggesting that this property differentiates clinically evaluated histamine H3 receptor antagonists and may play a role in their efficacy.
Collapse
Affiliation(s)
- Darren M Riddy
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Anna E Cook
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - David M Shackleford
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Tracie L Pierce
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Elisabeth Mocaer
- Institut de Recherches Internationales Servier, 50 Rue Carnot, 92284, Suresnes, France
| | | | - Aurore Sors
- Institut de Recherches Internationales Servier, 50 Rue Carnot, 92284, Suresnes, France
| | - William N Charman
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Roger J Summers
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Patrick M Sexton
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Arthur Christopoulos
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Christopher J Langmead
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
| |
Collapse
|
6
|
Sors A, Dudouet P, Franck D, Macé M, Boucarut P, Boutry C. PO-0890: EPID for QA and pre-treatment verification of electron beams in absolute dose using EpiDream method. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31200-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
7
|
Chaumette T, Chapuy E, Berrocoso E, Llorca-Torralba M, Bravo L, Mico JA, Chalus M, Eschalier A, Ardid D, Marchand F, Sors A. Effects of S 38093, an antagonist/inverse agonist of histamine H3 receptors, in models of neuropathic pain in rats. Eur J Pain 2017; 22:127-141. [PMID: 28877402 DOI: 10.1002/ejp.1097] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/30/2017] [Indexed: 11/08/2022]
Abstract
BACKGROUND Histamine H3 receptors are mainly expressed on CNS neurons, particularly along the nociceptive pathways. The potential involvement of these receptors in pain processing has been suggested using H3 receptor inverse agonists. METHODS The antinociceptive effect of S 38093, a novel inverse agonist of H3 receptors, has been evaluated in several neuropathic pain models in rat and compared with those of gabapentin and pregabalin. RESULTS While S 38093 did not change vocalization thresholds to paw pressure in healthy rats, it exhibited a significant antihyperalgesic effect in the Streptozocin-induced diabetic (STZ) neuropathy model after acute and chronic administration and, in the chronic constriction injury (CCI) model only after chronic administration, submitted to the paw-pressure test. Acute S 38093 administration at all doses tested displayed a significant cold antiallodynic effect in a model of acute or repeated administration of oxaliplatin-induced neuropathy submitted to cold tail immersion, cold allodynia being the main side effect of oxaliplatin in patients. The effect of S 38093 increased following chronic administration (i.e. twice a day during 5 days) in the CCI and STZ models except in the oxaliplatin models where its effect was already maximal from the first administration The kinetics and size of effect of S 38093 were similar to gabapentin and/or pregabalin. Finally, the antinociceptive effect of S 38093 could be partially mediated by α2 adrenoreceptors desensitization in the locus coeruleus. CONCLUSIONS These results highlight the interest of S 38093 to relieve neuropathic pain and warrant clinical trials especially in chemotherapeutic agent-induced neuropathic pain. SIGNIFICANCE S 38093, a new H3 antagonist/inverse agonist, displays antiallodynic and antihyperalgesic effect in neuropathic pain, especially in oxaliplatin-induced neuropathy after chronic administration. This effect of S 38093 in neuropathic pain could be partly mediated by α2 receptors desensitization in the locus coeruleus.
Collapse
Affiliation(s)
- T Chaumette
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - E Chapuy
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - E Berrocoso
- Neuropsychopharmacology and Psychobiology Research Laboratory, University of Cádiz, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
| | - M Llorca-Torralba
- Neuropsychopharmacology and Psychobiology Research Laboratory, University of Cádiz, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.,Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain
| | - L Bravo
- Neuropsychopharmacology and Psychobiology Research Laboratory, University of Cádiz, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.,Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain
| | - J A Mico
- Neuropsychopharmacology and Psychobiology Research Laboratory, University of Cádiz, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.,Instituto de Investigación e Innovación en Ciencias Biomédicas de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain
| | - M Chalus
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - A Eschalier
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - D Ardid
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - F Marchand
- Université Clermont Auvergne, Inserm U1107 Neuro-Dol, Pharmacologie Fondamentale et Clinique de la Douleur, Clermont-Ferrand, France
| | - A Sors
- Institut de Recherches Internationales Servier (I.R.I.S.), Suresnes Cedex, France
| |
Collapse
|
8
|
Panayi F, Sors A, Bert L, Martin B, Rollin-Jego G, Billiras R, Carrié I, Albinet K, Danober L, Rogez N, Thomas JY, Pira L, Bertaina-Anglade V, Lestage P. In vivo pharmacological profile of S 38093, a novel histamine H3 receptor inverse agonist. Eur J Pharmacol 2017; 803:1-10. [DOI: 10.1016/j.ejphar.2017.03.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Revised: 03/07/2017] [Accepted: 03/10/2017] [Indexed: 11/25/2022]
|
9
|
Sors A, Panayi F, Bert L, Favale D, Nosjean O, Audinot V, Arrang JM, Buisson B, Steidl E, Delbos JM, Huhtala T, Kontkanen O, Chollet AM, Casara P, Lestage P. Mechanistic characterization of S 38093, a novel inverse agonist at histamine H3 receptors. Eur J Pharmacol 2017; 803:11-23. [PMID: 28336400 DOI: 10.1016/j.ejphar.2017.03.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Revised: 03/07/2017] [Accepted: 03/10/2017] [Indexed: 11/16/2022]
Abstract
Histaminergic H3 inverse agonists, by stimulating central histamine release, represent attractive drug candidates to treat cognitive disorders. The present studies aimed to describe the mechanistic profile of S 38093 a novel H3 receptors inverse agonist. S 38093 displays a moderate affinity for rat, mouse and human H3 receptors (Ki=8.8, 1.44 and 1.2µM, respectively) with no affinity for other histaminergic receptors. In cellular models, the compound was able to antagonize mice H3 receptors (KB=0.65µM) and to suppress cAMP decrease induced by an H3 agonist via human H3 receptors (KB=0.11µM). The antagonism properties of the compound were confirmed by electrophysiological studies on rat hippocampal slices (from 0.1μM). In cells expressing a high H3 density, S 38093 behaved as a moderate inverse agonist at rat and human H3 receptors (EC50=9 and 1.7µM, respectively). S 38093 was rapidly absorbed in mouse and rat (Tmax=0.25-0.5h), slowly in monkey (2h), with a bioavailability ranging from 20% to 60% and t1/2 ranging from 1.5 to 7.4h. The compound was widely distributed with a moderate volume of distribution and low protein binding. The brain distribution of S 38093 was rapid and high. In mice, S 38093 significantly increased ex vivo N-tele-Methylhistamine cerebral levels from 3mg/kg p.o. and antagonized R-α-Methylhistamine-induced dipsogenia from 10mg/kg i.p. Taken together, these data suggest that S 38093, a novel H3 inverse agonist, is a good candidate for further in vivo evaluations, in particular in animal models of cognition.
Collapse
Affiliation(s)
- Aurore Sors
- Pôle d'Innovation Thérapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France.
| | - Fany Panayi
- Pôle d'Innovation Thérapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France
| | - Lionel Bert
- Pôle d'Innovation Thérapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France
| | - Dominique Favale
- Pôle d'Innovation Thérapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France
| | - Olivier Nosjean
- Pôle d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orléans, France
| | - Valérie Audinot
- Pôle d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orléans, France
| | | | | | | | - Jean-Marie Delbos
- Pôle d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orléans, France
| | - Tuulia Huhtala
- Charles River Discovery Research Services, Kuopio, Finland
| | - Outi Kontkanen
- Charles River Discovery Research Services, Kuopio, Finland
| | - Anne-Marie Chollet
- Pôle d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orléans, France
| | - Patrick Casara
- Pôle d'Expertise Recherche et Biopharmacie, Servier, Croissy-sur-Seine et Orléans, France
| | - Pierre Lestage
- Pôle d'Innovation Thérapeutique Neuropsychiatrie Servier, Croissy-sur-Seine et Suresnes, France
| |
Collapse
|
10
|
Sors A, Krazem A, Kehr J, Yoshitake T, Dominguez G, Henkous N, Letondor C, Mocaer E, Béracochéa DJ. The Synergistic Enhancing-Memory Effect of Donepezil and S 38093 (a Histamine H 3 Antagonist) Is Mediated by Increased Neural Activity in the Septo-hippocampal Circuitry in Middle-Aged Mice. Front Pharmacol 2016; 7:492. [PMID: 28066242 PMCID: PMC5177663 DOI: 10.3389/fphar.2016.00492] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2016] [Accepted: 12/01/2016] [Indexed: 01/01/2023] Open
Abstract
Donepezil, an acetylcholinesterase inhibitor, induces only moderate symptomatic effects on memory in Alzheimer’s disease patients. An alternative strategy for treatment of cognitive symptoms could be to act simultaneously on both histaminergic and cholinergic pathways, to create a synergistic effect. To that aim, 14 month old C57/Bl6 mice were administered per oesophagy during nine consecutive days with Donepezil (at 0.1 and 0.3 mg/kg) and S 38093 (at 0.1, 0.3, and 1.0 mg/kg), a H3 histaminergic antagonist developed by Servier, alone or in combination and tested for memory in a contextual memory task that modelized the age-induced memory dysfunction. The present study shows that the combination of Donepezil and S 38093 induced a dose-dependent synergistic memory-enhancing effect in middle-aged mice with a statistically higher size of effect never obtained with compounds alone and without any pharmacokinetic interaction between both compounds. We demonstrated that the memory-enhancing effect of the S 38093 and Donepezil combination is mediated by its action on the septo-hippocampal circuitry, since it canceled out the reduction of CREB phosphorylation (pCREB) observed in these brain areas in vehicle-treated middle-aged animals. Overall, the effects of drug combinations on pCREB in the hippocampus indicate that the synergistic promnesiant effects of the combination on memory performance in middle-aged mice stem primarily from an enhancement of neural activity in the septo-hippocampal system.
Collapse
Affiliation(s)
- Aurore Sors
- Pôle d'Innovation Thérapeutique Neuropsychiatrie Servier Suresnes, France
| | - Ali Krazem
- CNRS 5287, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Université de Bordeaux UMR, Pessac, France
| | - Jan Kehr
- Pronexus Analytical AB Bromma, Sweden
| | - Takashi Yoshitake
- Section of Pharmacological Neurochemistry, Department of Physiology and Pharmacology, Karolinska Institute Stockholm, Sweden
| | - Gaelle Dominguez
- CNRS 5287, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Université de Bordeaux UMR, Pessac, France
| | - Nadia Henkous
- CNRS 5287, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Université de Bordeaux UMR, Pessac, France
| | - Claire Letondor
- Pôle d'Innovation Thérapeutique Neuropsychiatrie Servier Suresnes, France
| | - Elisabeth Mocaer
- Pôle d'Innovation Thérapeutique Neuropsychiatrie Servier Suresnes, France
| | - Daniel J Béracochéa
- CNRS 5287, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Université de Bordeaux UMR, Pessac, France
| |
Collapse
|
11
|
Sors A, Dudouet P, Franck D, Boutry C. 26. Evaluation of the EpiDream method for quality assurance (QA) of electron beams using a Varian electronic portal imaging device (EPID). Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.11.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Sors A, Cassol E, Latorzeff I, Duthil P, Sabatier J, Lotterie JA, Redon A, Berry I, Franceries X. In-vivo dosimetry for field sizes down to 6 × 6 mm2 in shaped beam radiosurgery with microMOSFET. Phys Med 2014; 30:696-701. [PMID: 24743040 DOI: 10.1016/j.ejmp.2014.02.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 01/20/2014] [Accepted: 02/20/2014] [Indexed: 11/19/2022] Open
Abstract
The aim of this study is to evaluate microMOSFET as in-vivo dosimeter in 6 MV shaped-beam radiosurgery for field sizes down to 6 × 6 mm2. A homemade build-up cap was developed and its use with microMOSFET was evaluated down to 6 × 6 mm2. The study with the homemade build-up cap was performed considering its influence on field size over-cover occurring at surface, achievement of the overall process of electronic equilibrium, dose deposition along beam axis and dose attenuation. An optimized calibration method has been validated using MOSFET in shaped-beam radiosurgery for field sizes from 98 × 98 down to 18 × 18 mm2. The method was detailed in a previous study and validated in irregular field shapes series measurements performed on a head phantom. The optimized calibration method was applied to microMOSFET equipped with homemade build-up cap down to 6 × 6 mm2. Using the same irregular field shapes, dose measurements were performed on head phantom. MicroMOSFET results were compared to previous MOSFET ones. Additional irregular field shapes down to 8.8 × 8.8 mm2 were studied with microMOSFET. Isocenter dose attenuation due to the homemade build-up cap over the microMOSFET was near 2% irrespective of field size. Our results suggested that microMOSFET equipped with homemade build-up cap is suitable for in-vivo dosimetry in shaped-beam radiosurgery for field sizes down to 6 × 6 mm2 and therefore that the required build-up cap dimensions to perform entrance in-vivo dosimetry in small-fields have to ensure only partial charge particle equilibrium.
Collapse
Affiliation(s)
- A Sors
- Inserm Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Centre de Radiochirurgie Stéréotaxique, CHU Rangueil, Toulouse, France.
| | - E Cassol
- Inserm Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Unité de Radiophysique et de Radioprotection, CHU Toulouse, France
| | - I Latorzeff
- Centre de Radiochirurgie Stéréotaxique, CHU Rangueil, Toulouse, France; Groupe Oncorad Garonne, France
| | - P Duthil
- Unité de Radiophysique et de Radioprotection, CHU Toulouse, France
| | - J Sabatier
- Centre de Radiochirurgie Stéréotaxique, CHU Rangueil, Toulouse, France
| | - J A Lotterie
- Inserm Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Centre de Radiochirurgie Stéréotaxique, CHU Rangueil, Toulouse, France
| | - A Redon
- Centre de Radiochirurgie Stéréotaxique, CHU Rangueil, Toulouse, France; Groupe Oncorad Garonne, France
| | - I Berry
- Inserm Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Centre de Radiochirurgie Stéréotaxique, CHU Rangueil, Toulouse, France
| | - X Franceries
- Inserm Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Université de Toulouse, UPS, INPT, LAPLACE Laboratoire Plasma et Conversion d'Energie, 118 route de Narbonne, F-31062 Toulouse cedex 9, France; Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France
| |
Collapse
|
13
|
Sors A, Cassol E, Latorzeff I, Duthil P, Sabatier J, Lotterie J, Redon A, Berry I, Franceries X. Inverse method for in vivo dosimetry using mosfet in conformal arctherapy for stereotactic radiosurgery. Phys Med 2013. [DOI: 10.1016/j.ejmp.2013.08.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
14
|
Sors A, Cassol E, Latorzeff I, Duthil P, Sabatier J, Lotterie JA, Redon A, Berry I, Franceries X. An optimized calibration method for surface measurements with MOSFETs in shaped-beam radiosurgery. Phys Med 2013; 30:10-7. [PMID: 23623590 DOI: 10.1016/j.ejmp.2013.03.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2012] [Revised: 03/11/2013] [Accepted: 03/14/2013] [Indexed: 11/27/2022] Open
Abstract
Nowadays MOSFET dosimeters are widely used for dose verification in radiotherapy procedures. Although their sensitive area satisfies size requirements for small field dosimetry, their use in radiosurgery has rarely been reported. The aim of this study is to propose and optimize a calibration method to perform surface measurements in 6 MV shaped-beam radiosurgery for field sizes down to 18 × 18 mm(2). The effect of different parameters such as recovery time between 2 readings, batch uniformity and build-up cap attenuation was studied. Batch uniformity was found to be within 2% and isocenter dose attenuation due to the build-up cap over the MOSFET was near 2% irrespective of field size. Two sets of sensitivity coefficients (SC) were determined for TN-502RD MOSFET dosimeters using experimental and calculated calibration; the latter being developed using an inverse square law model. Validation measurements were performed on a realistic head phantom in irregular fields. MOSFET dose values obtained by applying either measured or calculated SC were compared. For calibration, optimal results were obtained for an inter-measurement time lapse of 5 min. We also found that fitting the SC values with the inverse square law reduced the number of measurements required for calibration. The study demonstrated that combining inverse square law and Sterling-Worthley formula resulted in an underestimation of up to 4% of the dose measured by MOSFETs for complex beam geometries. With the inverse square law, it is possible to reduce the number of measurements required for calibration for multiple field-SSD combinations. Our results suggested that MOSFETs are suitable sensors for dosimetry when used at the surface in shaped-beam radiosurgery down to 18 × 18 mm(2).
Collapse
Affiliation(s)
- A Sors
- Inserm, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Centre de Radiochirurgie Stéréotaxique, Biophysique Médicale - CHU Rangueil, av. J. Poulhès - TSA 50032, 31059 Toulouse Cedex 9, France.
| | - E Cassol
- Inserm, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Unité de Radiophysique et de Radioprotection, CHU Toulouse, France
| | - I Latorzeff
- Centre de Radiochirurgie Stéréotaxique, Biophysique Médicale - CHU Rangueil, av. J. Poulhès - TSA 50032, 31059 Toulouse Cedex 9, France; Groupe Oncorad Garonne, France
| | - P Duthil
- Unité de Radiophysique et de Radioprotection, CHU Toulouse, France
| | - J Sabatier
- Centre de Radiochirurgie Stéréotaxique, Biophysique Médicale - CHU Rangueil, av. J. Poulhès - TSA 50032, 31059 Toulouse Cedex 9, France
| | - J A Lotterie
- Inserm, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Centre de Radiochirurgie Stéréotaxique, Biophysique Médicale - CHU Rangueil, av. J. Poulhès - TSA 50032, 31059 Toulouse Cedex 9, France
| | - A Redon
- Centre de Radiochirurgie Stéréotaxique, Biophysique Médicale - CHU Rangueil, av. J. Poulhès - TSA 50032, 31059 Toulouse Cedex 9, France; Groupe Oncorad Garonne, France
| | - I Berry
- Inserm, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Centre de Radiochirurgie Stéréotaxique, Biophysique Médicale - CHU Rangueil, av. J. Poulhès - TSA 50032, 31059 Toulouse Cedex 9, France
| | - X Franceries
- Inserm, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France; Université de Toulouse, UPS, INPT, LAPLACE Laboratoire Plasma et Conversion d'Energie, 118 route de Narbonne, F-31062 Toulouse Cedex 9, France; Universitéde Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France
| |
Collapse
|
15
|
Sors A, Cassol E, Latorzeff I, Duthil P, Lotterie J, Redon A, Berry I, Franceries X. Micro-mosfet For Small-field In Vivo Dosimetry In Radiosurgery? Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
16
|
Camilleri J, Laprie A, Sors A, Kerjean P, Kerjean JC, Gros-Dagnac H, Moyal É, Delannes M, Franceries X. Doit-on changer la technique d’utilisation des bolus en radiothérapie des cancers cutanés ? Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
17
|
Sors A, Cassol E, Hallil A, Latorzeff I, Duthil P, Lotterie JA, Redon A, Berry I, Franceries X. Optimisation de la calibration de MOSFET pour la dosimétrie in vivo en radiochirurgie : réduction des incertitudes de mesure en conditions précliniques. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Sors A, Cassol E, Hallil A, Latorzeff I, Duthil P, Lotterie JA, Redon A, Berry I, Franceries X. Optimisation de la calibration de capteurs de type MOSFET pour la mise en œuvre de la dosimétrie in vivo en radiochirurgie stéréotaxique. Cancer Radiother 2010. [DOI: 10.1016/j.canrad.2010.07.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
19
|
Sors A, Jean-Louis F, Bégué E, Parmentier L, Dubertret L, Dreano M, Courtois G, Bachelez H, Michel L. Inhibition of IκB Kinase Subunit 2 in Cutaneous T-Cell Lymphoma Down-Regulates Nuclear Factor-κB Constitutive Activation, Induces Cell Death, and Potentiates the Apoptotic Response to Antineoplastic Chemotherapeutic Agents. Clin Cancer Res 2008; 14:901-11. [DOI: 10.1158/1078-0432.ccr-07-1419] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, Courtois G, Bachelez H, Michel L. Down-regulating constitutive activation of the NF-κB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006; 107:2354-63. [PMID: 16219794 DOI: 10.1182/blood-2005-06-2536] [Citation(s) in RCA: 135] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
AbstractConstitutive activation of the nuclear factor-kappaB (NF-κB) pathway has been shown to be involved in the resistance of tumor cells to apoptosis in several human malignancies of the hematopoietic lineage. By using electrophoretic mobility shift assay (EMSA) and confocal microscopic analysis, we demonstrate that NF-κB is constitutively activated in cutaneous T-cell lymphoma (CTCL) cell lines HuT-78, MyLa, and SeAx and in peripheral blood lymphocytes (PBLs) from patients with Sézary syndrome (SS) presenting a high ratio of tumor cells, with evidence of p50 and RelA/p65 in DNA-linked complexes. Transfection of SeAx line with a κB/luciferase reporter plasmid showed that translocated NF-κB complexes were functional. Selective inhibition of NF-κB, by transfecting CTCL cell lines with a super-repressor form of IκBα, led to apoptosis. We evidenced down-regulation of NF-κB activation and induction of CTCL cell apoptosis in the presence of proteasome 26S inhibitors ALLN, MG132, and bortezomib. Bortezomib at nanomolar concentrations inhibited constitutive activation of NF-κB and induced apoptosis of CTCL cells, with evidence of an upregulation of Bax expression. These results demonstrate the key role played by NF-κB in the resistance of CTCL to apoptosis and suggest that bortezomib might be useful for the treatment of patients with advanced stages of CTCL refractory to standard antineoplastic chemotherapy.
Collapse
Affiliation(s)
- Aurore Sors
- INSERM U697, Institut de Recherche sur la Peau, Pavillon Bazin, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris cedex 10, France
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Michel L, Pellet C, Sors A, Jean louis F, Lebart M, Courtois G, Bachelez H. C21 - Expression de la t-plastine dans les lymphomes T cutanés. Ann Dermatol Venereol 2005. [DOI: 10.1016/s0151-9638(05)79642-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
22
|
Michel L, Dupuy A, Jean-Louis F, Sors A, Poupon J, Viguier M, Musette P, Dubertret L, Degos L, Dombret H, Bachelez H. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol 2003; 121:881-93. [PMID: 14632209 DOI: 10.1046/j.1523-1747.2003.12479.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Arsenic trioxide (As2O3) displays apoptogenic properties against various types of hematopoietic malignancies. We investigated the effects of As2O3 on the viability of the cutaneous T cell lymphoma cell lines HuT-78, SeAx, and Myla, and of peripheral blood mononuclear cells from patients with Sézary syndrome, by using propidium iodide and annexin-V staining, terminal deoxyuridine triphosphate nick end labeling (TUNEL), cell cycle analysis, mitochondrial transmembrane potential (delta psi(m)) alterations, cytochrome c release, and detection of processed caspase-3. We also report in vivo effects of As2O3 in two patients with cutaneous T cell lymphoma. The results show that As2O3 induces apoptosis of cutaneous T cell lymphoma lines and of Sézary cells from patients in a time- and concentration-dependent manner in vitro, as demonstrated by annexin-V staining, mitochondrial depolarization, and DNA fragmentation. Ascorbic acid 100 microM potentiated As2O3-induced Sézary cell death, whereas interferon-alpha had no synergistic effect. As2O3-induced Sézary cell death involves activation of caspase-3, cleavage of poly(ADP-ribose)polymerase, and cytochrome c release, but was only partially inhibited by the pancaspase inhibitor Z-VAD.fluoromethylketone. Finally, As2O3 was administered to two patients with cutaneous T cell lymphoma, allowing us to obtain a partial response in one case, whereas stability was observed in the second patient. These results demonstrate that As2O3 synergizes with ascorbic acid to induce Sézary cell death at clinically achievable concentrations, through a caspase-partially independent pathway, and provide a rationale for further in vivo studies addressing the therapeutic efficacy of As2O3 in cutaneous T cell lymphoma patients.
Collapse
Affiliation(s)
- Laurence Michel
- Skin Research Institute, Institut National de la Santé et de la Recherche Médicale U532, Department of Dermatology, Hôpital Saint-Louis, Paris, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
Within the framework of its' Environment Research and Development Programme, the European Communities (EC) Directorate General (DG) XII has supported a research project aimed at developing and validating assay systems for the detection and evaluation of chemicals capable of inducing numerical chromosome changes such as aneuploidy and polyploidy. A range of test chemicals were selected, which include a core set comprising; colchicine, econazole nitrate, chloral hydrate, hydroquinone, diazepam, thiabendazole, cadmium chloride, thimerosol, pyrimethamine and vinblastine sulphate. These test chemicals were used to evaluate the ability of test systems ranging from tubulin polymerisation, fungal cultures, cultured mammalian cells and intact rodents to detect chemical aneugens and to assess the significance of such activity to exposed human populations.
Collapse
Affiliation(s)
- J M Parry
- School of Biological Sciences, University College of Swansea, UK
| | | |
Collapse
|
24
|
Sors A. Change of address. Environ Monit Assess 1982; 1:188. [PMID: 24264012 DOI: 10.1007/bf00676920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|